Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses. New peer-reviewed research, out today in Science, demonstrates the vaccine platform provides protection against a spectrum of…
Biotechnology company Ingenza is delighted to announce that its recent partnership with Johnson Matthey has been selected to receive vital funding of £441,632.88 from the Department of Business, Energy and Industrial Strategy as part of the £1 billion fund from the…
Biotechnology company Ingenza is excited to report the successful conclusion to its recent six-month project with Johnson Matthey, a speciality chemicals and sustainable technologies supplier. Together, the companies have developed new, efficient approaches for the production of industrially-relevant enzymes –…
Ingenza is thrilled to have received support for its Unleashing Putida: Biobased Methacrylates for a Sustainable Future project with the award of a grant from Innovate UK and Eureka. This ground-breaking research is being undertaken in collaboration with Mitsubishi Chemical…
Ingenza is pleased to announce the award of two Innovate UK Sustainable Innovation Fund grants amounting to £232K. These grants will support two cutting edge projects in carbon use efficiency, which will reap major benefits for Ingenza while supporting the…
Biotechnology company Ingenza is proud to be celebrating its 10th year of collaboration with Teesside-based Lucite International (LI). LI is the world’s largest producer of methyl-methacrylate (MMA) – the building block of acrylic – and has partnered with Ingenza to…
Dr Ian Fotheringham, Managing Director and founder of Ingenza, has been awarded an MBE for services to Industrial Biotechnology in the Queen’s Birthday Honours List. This accolade recognises Ian’s position as a well-known industrial biotechnology expert. He originally gained extensive…
Ingenza’s ambitious SYNBIOPRO project for the development of biopharmaceuticals continues to make significant progress, despite the global disruption caused by the COVID-19 pandemic. Supported by a Scottish Enterprise research and development (R&D) grant since 2018, this project has hit a…
Ingenza has reached an important milestone in its work to develop a low cost recombinant human factor VIII (rhFVIII) production process to make materials for ProFactor Pharma Ltd (PFP). The goal of this work is to enable PFP to transform…
Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Ingenza has been working closely with researchers at Oxford University…